雄激素对再生障碍性贫血患者端粒长度影响的研究#br#

［摘要］ 目的探讨雄激素对再生障碍性贫血（aplastic anemia，AA）患者端粒长度的影响以及端粒在AA发病机制中的作用。 方法依据临床诊断标准收集AA患者30例，分为环孢素A（cyclosporin A，CsA）+雄激素组和CsA组各15例。应用核酸提取仪及核酸提取试剂盒提取外周血基因组DNA；采用实时荧光定量PCR检测外周血白细胞端粒相对长度，并与15例健康对照组进行比较。 结果AA患者基线端粒长度相对T/S比率低于对照组（P＜0.05）。治疗后,CsA组端粒长度相对T/S比率波动降低，CsA+雄激素组端粒长度相对T/S比率逐渐升高，CsA+雄激素组端粒长度相对T/S比率高于CsA组，其组间、时点间、组间·时点间交互作用差异均有统计学意义（P＜0.05）。治疗后12个月时CsA+雄激素组血液学改善率高于CsA组（P＜0.05）。 结论雄激素可以调节AA患者端粒长度，雄激素治疗后AA患者端粒长度增加。雄激素在治疗AA伴端粒功能障碍方面是有效的，可以获得有临床意义的血液学改善。

Effect of androgen on telomeres length in aplastic anemia patients

［Abstract］Objective〖HTSS〗To explore the effect of androgen on telomeres in aplastic anemia（AA） patients, and the effect of telomeres in the pathogenesis of AA. Methods〖HTSS〗The patients were collected according to the AA clinical diagnostic criteria. They were divided into two groups, cyclosporin A(CsA)+androgen and CsA respectively, 15 cases in each group. The genomic DNA of peripheral blood was extracted by nucleic acid extractor and nucleic acid extraction kit. The relative length of telomere in peripheral blood leukocytes was measured by real-time fluorescence quantitative PCR and compared with that of 15 healthy controls. Results〖HTSS〗The relative T/S ratio of the telomere length in AA patients was significantly shorter than that in the normal control group(P＜0.05). After treatment, the relative T/S ratio of the telomere length in the CsA group was reduced volatility,and that of the CsA+androgen group was increased. The relative T/S ratio of the telomere length in the CsA+androgen group was evidently higher than that in the CsA group.The differences between groups,time points, interaction of groups and time points were statistically significant(P＜0.05). The hematological improvement of CsA+androgen was better than that of CsA group at 12 months after treatment(P＜0.05). Conclusion〖HTSS〗Androgen can regulate telomere length in AA patients, and the length of telomeres increased after androgen therapy. Androgen is effective in the treatment of AA with telomere dysfunction, and clinical hematologic improvement can be achieved.